By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Azur Pharma Inc. 

1818 Market Street
Suite 2350
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-832-3750 Fax: 215-832-3789



Company News
Jazz Pharmaceuticals, Inc. (JAZZ) and Azur Pharma Inc. Combine to Create Jazz Pharmaceuticals plc 1/18/2012 7:25:24 AM
Jazz Pharmaceuticals, Inc. (JAZZ) to Hold Investor Conference Call on January 5 to Discuss 2012 Financial Guidance and Azur Pharma Inc. Transaction 1/4/2012 10:05:20 AM
Azur Pharma Inc. Release; 2011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 12/19/2011 10:50:06 AM
Jazz Pharmaceuticals, Inc. (JAZZ) Announces Stockholder Vote in Favor of Transaction With Azur Pharma Inc. 12/13/2011 9:23:41 AM
Jazz Pharmaceuticals, Inc. (JAZZ) Soars as Analyst Praises Move to Buy Azur Pharma Inc.; Companies Combine to Form Jazz Pharmaceuticals plc 9/20/2011 5:58:54 AM
BioSante Pharmaceuticals, Inc. (BPAX) Reports Receipt of $2.16 Million in Elestrin(TM) Royalty Buydown With Azur Pharma Inc., and Financial Results for 2009 3/30/2010 9:06:32 AM
Azur Pharma Inc. to Acquire Elan Corporation PLC (ELN)'s Painkiller Prialt 3/12/2010 7:34:08 AM
Azur Pharma Inc. Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan CNS/Pain Specialty Infrastructure 3/11/2010 8:36:51 AM
Azur Pharma Inc. Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB Two Marketed CNS Products With U.S. Revenues of $20 Million Two FDA Approved but Unlaunched Products 1/9/2009 9:56:19 AM
Antares Pharma, Inc. (ANTR) Receives Milestone Payment and Additional Patent Related to Elestrin(R) 1/6/2009 8:44:32 AM